| 33.78 0.99 (3.02%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.35 | 1-year : | 46.97 |
| Resists | First : | 36.26 | Second : | 40.22 |
| Pivot price | 32.8  |
|||
| Supports | First : | 29.86 | Second : | 24.84 |
| MAs | MA(5) : | 32.77  |
MA(20) : | 33.6 |
| MA(100) : | 32.02 |
MA(250) : | 22.83 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 54.6 |
D(3) : | 42.2 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 40.22 | Low : | 5.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ STOK ] has closed below upper band by 18.9%. Bollinger Bands are 54.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 34.12 - 34.25 | 34.25 - 34.38 |
| Low: | 31.5 - 31.65 | 31.65 - 31.8 |
| Close: | 33.53 - 33.77 | 33.77 - 34.01 |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Tue, 07 Apr 2026
Stoke Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Tue, 07 Apr 2026
Stoke Therapeutics (STOK) director receives 30,782-share stock option grant - Stock Titan
Tue, 07 Apr 2026
Stoke Therapeutics (STOK) director Kahn Clare submits initial Form 3 insider report - Stock Titan
Tue, 07 Apr 2026
Clare Kahn joins Stoke Therapeutics (Nasdaq: STOK) board, receives option grant - Stock Titan
Tue, 07 Apr 2026
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors - businesswire.com
Fri, 03 Apr 2026
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 4.383e+007 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 11,800 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.882e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -3.8 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 382.2 % |
| Return on Equity (ttm) | -3.8 % |
| Qtrly Rev. Growth | 1.8442e+008 % |
| Gross Profit (p.s.) | -78.83 |
| Sales Per Share | -2 |
| EBITDA (p.s.) | 1.54975e+008 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 46 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -16.97 |
| Price to Cash Flow | 6.72 |
| Dividend | 0 |
| Forward Dividend | 1.338e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|